Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you are a long-term Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shareholder, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/regeneron-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? On May 15, 2026, Regeneron issued a press release disclosing that "results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." Following this news, Regeneron's stock price dropped $68.57 per share, or 9.82%, to close at $629.68 on May 16, 2026.

WHAT CAN YOU DO NOW? If you are a long-term Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shareholder, you are encouraged to visit https://grabarlaw.com/the-latest/regeneron-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

#REGN #Regeneron $REGN

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298752

Source: Grabar Law Office